Legislation Details

File #: 14081   
Type: Consent Status: Passed
File created: 4/27/2026 Department: Arrowhead Regional Medical Center
On agenda: 5/5/2026 Final action: 5/5/2026
Subject: Amendment to Contract with Endologix, LLC for the Provision of Percutaneous Arterial Bypass Graft and Endovascular Products
Attachments: 1. CON - ARMC - 5-5-26 - Endologix LLC A1, 2. Item #12 Executed BAI, 3. 24-934 A-1 Executed Contract

REPORT/RECOMMENDATION TO THE BOARD OF SUPERVISORS

OF SAN BERNARDINO COUNTY

AND RECORD OF ACTION

 

                                          May 5, 2026

 

FROM

ANDREW GOLDFRACH, ARMC Chief Executive Officer, Arrowhead Regional Medical Center 

         

SUBJECT                      

Title                     

Amendment to Contract with Endologix, LLC for the Provision of Percutaneous Arterial Bypass Graft and Endovascular Products

End

 

RECOMMENDATION(S)

Recommendation

Approve Amendment No. 1 to Contract No. 24-934 with Endologix, LLC for the provision of percutaneous arterial bypass graft and endovascular products, increasing the contract amount by $480,000, from an amount not to exceed $480,000, to an amount not to exceed $960,000, and extending the term for two years, for a total term of September 24, 2024 through May 31, 2028.

(Presenter: Andrew Goldfrach, ARMC Chief Executive Officer, 580-6150)

Body

 

COUNTY AND CHIEF EXECUTIVE OFFICER GOALS & OBJECTIVES

Provide for the Safety, Health and Social Service Needs of County Residents.

 

FINANCIAL IMPACT

Approval of this item will not result in the use of Discretionary General Funding (Net County Cost). The cost of $480,000 is funded by the State Medi-Cal, Federal Medicare, private insurances, and other departmental revenue. Funding sources may change in the future pending any legislative activity related to the repeal and/or replacement of the Affordable Care Act. Adequate appropriation and revenue have been included in the Arrowhead Regional Medical Center (ARMC) 2025-26 budget and will be included in future recommended budgets.

 

BACKGROUND INFORMATION

Amendment No. 1 (Amendment) with Endologix, LLC (Endologix) will allow ARMC to continue to purchase the Detour System and the ALTO Abdominal Stent Graft System (Products) for an additional two years. The Products allow physicians to treat superficial femoral artery disease and abdominal aortic aneurysms, respectively.

 

On September 24, 2025 (Item No. 19), as the result of a non-competitive procurement, the Board of Supervisors approved Contract No. 24-934 with Endologix for the provision of percutaneous arterial bypass graft and endovascular products, in an amount not to exceed $480,000, for the period of September 24, 2024 through May 31, 2026.

 

ARMC recommends approval of the Amendment as the continued purchase of the Products will provide for the safety and health needs of county residents to treat superficial femoral artery disease and abdominal aortic aneurysms which may reduce patient length of stay, infection and other morbidity, and ensure proper care is provided to ARMC patients.

 

PROCUREMENT

Not applicable.

 

REVIEW BY OTHERS

This item has been reviewed by County Counsel (Charles Phan, Supervising Deputy County Counsel, 387-5455) on April 3, 2026; Purchasing (Veronica Pedace, Buyer III, 387-2464) on April 6, 2026; ARMC Finance (Chen Wu, Finance and Budget Officer, 580-3165) on April 10, 2026; and County Finance and Administration (Jenny Yang, Administrative Analyst, 387-4884) on April 13, 2026.